Related Experiment Video
Updated: May 2, 2026

Electrochemotherapy of Tumours
Published on: December 15, 2008
[Chemotherapy]
1Tochigi Cancer Center.
Abstract:
Chemotherapy for colorectal cancer has improved greatly and survival rate is improving. Now, we have many effective but toxic regimens (FOLFOX, CapeOX, FOLFIRI, FOLFOXIRI with or without bevacizumab or cetuximab or panitumumab) and regorafenib, a multikinase inhibitor, can be used for third- or forth-line treatment. Treatments should be tailored to an individual patient according to tumor characteristics and patient conditions. Conversion therapy is secondary surgery after most active induction chemotherapy, e.g., FOLFOX with cetuximab. Conversion rate is about 10%. Adjuvant chemotherapy is indicated for stage III patients. 5FU+LV, UFT+LV, capecitabine, FOLFOX, CapeOX and S-1 are available in the adjuvant setting. Regimens including oxaliplatin should be prescribed to high-risk stage III patients, because of oxaliplatin toxicity.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies

